LCM Genect announces that subscriptions to the the seminar PHARMACOGENETICS: THE WAY TO FIND INDIVIDUAL THERAPY SOLUTIONS Present stage and Future trends April 10th, 2018 9.30 am – 12.30 pm San Raffaele Hospital Via Olgettina, 60 - 20132 Milan Have been extended until April 06th, 2018 Kindly confirm your presence with an e-mail at info@lcm-genect.com ...
Read More
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide. ELCC 2017, was held in Geneva, Switzerland on 5-8 May, has attracted more than 2,500 participants including medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and...
Read More
LCM Genect invites you at the company launch event, on November 24th, at SIGU National Congress, Centro Congressi Lingotto, Turin....
Read More“An effective clinic management of patients with advanced cancer requires at least two factors: an accurate classification of the patient and the choice of the most appropriate treatment through a precise evaluation of the patient’s activity”...
Read MoreThe question is how to prevent drug adverse events and the Pharmigene kits are the answer. In fact, Pharmigene’s main goal is to innovate and commercialize Real Time diagnostic CE – IVD tests focused on ADRs (Adverse Drug Reactions) that enable individuals to be better informed about their genomic makeup and to make decisions that can better their health. Although most adverse drug events can be...
Read MoreLCM Genect will partecipate in the 19th National Congress of the Italian Society of Human Genetics (SIGU) from 23rd to 26th November, booth n° 7 The 19th National Congress of the Italian Society of Human Genetics (SIGU) will take place at the Lingotto Congress Centre in Turin. As in previous years, the programme has been drawn up on the basis of SIGU member suggestions. Plenary and parallel sessions have been organised. The...
Read MorePresented at ASCO 2016 the outcomes of the OxOnc Study in which the test has properly supported the completion of a Phase 2 study of crizotinib in patients with ROS1-Positive Non-Small Cell Lung Cancer The OxOnc Study met its primary objective of demonstrating a high overall response rate for crizotinib. It enrolled 127 ROS1-positive patients in the People’s Republic of China (PRC), Japan, Taiwan and South Korea...
Read More
